has entered a new chapter in its 100-year history — thanks to its newfound success with two products: Ozempic and Wegovy.
"It's clear that nobody had expected that it would be taking off this quickly," said Novo Nordisk CEO Lars Fruergaard Jørgensen in August."We all along knew that obesity was a serious chronic disease also when most others did not see it like that. So we knew we were onto something big." "There has not been any performance near what we've seen over the last year or two," said Jared Holz, health care sector specialist at Mizuho, adding that semaglutide alone could be worth up to $300 billion annually over time.
Portugal Últimas Notícias, Portugal Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Food Stocks Are Falling. Don't Blame Ozempic.Packaged-food stocks are in the red as of late, and it may indicate that consumers are shifting to fresh produce, meat, deli, and bakery products.
Consulte Mais informação »